Creative Edge Nutrition, Inc. (FITX: OTC Pink Current) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Creative Edge Nutrition, Inc. (FITX: OTC Pink Current) | Creative Edge Nutrition Inc. (FITX) Elects Dr. M. Kerry O'Banion, M.D., Ph.D to Its Board of Directors Creative Edge Nutrition Inc. (FITX) Elects Dr. M. Kerry O'Banion, M.D., Ph.D to Its Board of Directors

Creative Edge Nutrition Inc. (FITX) Elects Dr. M. Kerry O'Banion, M.D., Ph.D to Its Board of Directors

Highly Accomplished Internationally Recognized Scientist With Expertise in Neuroscience Further Strengthens Company's Board of Directors

MADISON HEIGHTS, MI--(Marketwired - May 23, 2014) -  Creative Edge Nutrition, Inc. (OTC Pink: FITX) ( PINKSHEETS : FITX ), is pleased to announce that it has elected Dr. M. Kerry O'Banion, M.D., Ph.D. to its Board of Directors.

Dr. O'Banion is an internationally recognized scientist specializing in brain inflammation, epilepsy, brain radiation, and many neurological disorders. A veteran, in neuroscience, Dr. O'Banion's current research focuses upon pro-inflammatory cytokines and lipid mediators in traumatic brain injury, Alzheimer's disease, radiation injury, and psychiatric illnesses.

"We are very fortunate to welcome such a respected industry leader to serve on our Board," stated Bill Chaaban, President & CEO. "Dr. Obanion brings both clinical knowledge and business acumen to CEN Biotech. He has his finger on the pulse of cutting edge treatment for patients living with neurological conditions and will undoubtedly be a critical resource for our development and use of providing ground breaking medicinal cannabis solutions."

Dr. O'Banion is a distinguished leader at the University of Rochester Medical Center where he directs the NIH-funded Medical Scientist Training Program as Principal Investigator and serves as the Director of Medical Neurosciences courses. Dr. O'Banion is a research leader in individual and program grants with an outstanding record of NIH funding. His research in neuroinflammation provided the mechanistic underpinnings that led to the development of Vioxx and Celebrex, the COX-2 inhibitor pain relievers, for which he and colleagues were awarded U.S. patents. As a result he was appointed Assistant Professor of Neurology, and initiated research into neuroinflammation and its role in neurodegenerative disease.

Dr. O'Banion received both his M.D. and Ph.D. degrees from the University of Illinois School of Medicine, Champaign-Urbana, IL, where he graduated Summa Cum Laude and served as valedictorian for his graduation class.

About CEN Biotech
CEN Biotech, Inc. was established in 2013 as a partially owned subsidiary of Creative Edge Nutrition (OTC Pink: FITX) ( PINKSHEETS : FITX ) for the sole purpose of supplying the Canadian public with pharmaceutical-grade medical cannabis under the newly established Marihuana for Medical Purposes Regulations (MMPR). CEN Biotech Inc. has submitted a comprehensive application to become a licensed producer (LP) of dried marihuana for medicinal purposes and has received a ready-to-build approval from Health Canada.
http://www.cenbiotechinc.com

About Creative Edge Nutrition, Inc.
Creative Edge Nutrition is a holding company and a Nutritional Supplement Company focused on developing innovative, high quality supplements. The company offers a broad spectrum of capsules, tablets, and powders, as well as science based products in the principal categories of weight management, nutrition challenges, energy and fitness. The Company manufactures under strict GMP guidelines at GMP Certified and/or FDA registered facilities. http://www.cenergynutrition.com and https://www.facebook.com/CenergyNutrition

Contact:
FOR INVESTOR RELATIONS
William Swalm
(212) 584-4342
Info@cenergynutrition.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 7

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 46

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Match2 Enhances HR Tech: Unified Talent Profile System

Updated Category News Views 8

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Continue Reading
Costa Rican Firms Chase Growth at SIAL Paris 2026

Updated Category News Views 4

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Continue Reading
Florida Cancer Center Expands Expertise with New Oncologist

Updated Category News Views 3

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 50

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
2GenPen & LordCap Team Up: Game-Changer in ABS?

Updated Category News Views 3

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Continue Reading
Tenant Improvement: Key to Adapting Lease Spaces

Updated Category News Views 0

Adapting Space or Adapting Business? Here's the thing that keeps popping up in commercial real estate: tenant improvement construction. This isn't just modifying a structure—it's about rethinking how businesses operate within a certain space. The HelloNation article gives you the lowdown straight from Bradley Quakenbush of White Oak Commercial Group. When businesses...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 35

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 46

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading

Top 5 Most Recently Viewed Articles

AAR Continues Strong Partnership With Collins Aerospace Products

Updated Category News Views 191

AAR Strengthens Ties with Collins Aerospace AAR CORP. (NYSE: AIR) has recently announced an extension of its exclusive global distribution agreement with Collins Aerospace, a division of RTX. This multi-year partnership focuses on the Goodrich de-icing and specialty systems product line. The agreement emphasizes AAR's commitment to supporting the needs of commercial and...

Continue Reading
Kontoor Brands Shares Exciting Third Quarter Earnings Update

Updated Category News Views 65

Kontoor Brands Announces Third Quarter Earnings Plans Kontoor Brands, Inc. (NYSE: KTB), a prominent player in the global lifestyle apparel sector, is gearing up for an important financial disclosure. The company, known for its highly-regarded Wrangler and Lee brands, has declared its intention to unveil third quarter earnings on a specified date. This announcement is set...

Continue Reading
Wendy's Stock Faces Market Challenges Yet Eyes Recovery

Updated Category News Views 833

Wendy's Stock Faces Market Challenges Yet Eyes Recovery The Wendy's Co (NASDAQ: WEN) has recently faced significant challenges in the stock market, hitting a 52-week low of $14.72. Known for its distinctive square burgers and delicious frosty desserts, Wendy's stock has struggled, reflecting broader market difficulties that are influencing investor sentiments. With a...

Continue Reading
Evoke Pharma Set to Announce Key Financial Results Soon

Updated Category News Views 104

Evoke Pharma Anticipates Financial Announcement Evoke Pharma, Inc. (NASDAQ: EVOK) is ushering in an important moment as it prepares to report its financial results for the fourth quarter and the entire year of 2024. This update is slated for release on a Thursday afternoon, following the closing of the markets. Such earnings reports are crucial for stakeholders keen on...

Continue Reading
JD.com Reports Impressive Q3 2024 Financial Performance

Updated Category News Views 408

A Closer Look at JD.com’s Q3 2024 Results JD.com, Inc. (NASDAQ: JD), a prominent technology and service provider in supply chain management, has recently revealed its financial outcomes for the third quarter of 2024. The company's results reflect its strategic advancements and robust operational performance amid the evolving e-commerce landscape. Financial Highlights In...

Continue Reading